PF-03654746

Phase 2Small molecule

PF-03654746 is one of 127 small molecule programs targeting Attention Deficit Hyperactivity Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

126

Competitors

Pipeline

Status by Indication[3][1]

Indication

Attention Deficit Hyperactivity DisorderActive, not recruiting

Allergic RhinitisActive, not recruiting

NarcolepsyActive, not recruiting

SchizophreniaActive, not recruiting

Attention Deficit Hyperactivity DisorderPhase 2

Active, not recruiting

Allergic RhinitisPhase 2

Active, not recruiting

NarcolepsyPhase 2

Active, not recruiting

SchizophreniaPhase 1

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

PF-03654746

Pfizer

Phase 2

1 2

Inapsine

Alnylam Pharmaceuticals

Preclinical

1 3

Ozempic

Novo Nordisk

Preclinical

1 4

Resotran

Takeda

Preclinical

1 5

Lunesta

Akero Therapeutics

Preclinical

3 6

Comtan

Orion Corporation, Orion Pharma

Preclinical

1 7

Persantine

Boehringer Ingelheim

Preclinical

1 8

Permax

VValeant Pharmaceuticals

Preclinical

1 9

Luvox

SSolvay Pharmaceuticals

Preclinical

1 10

Vivarin

HHikma Pharmaceuticals LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Allergic Rhinitis1 trial

A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge

Completed· Pfizer logo

Pfizer·Phase 2·NCT00562120·21 enrolled

Attention Deficit Hyperactivity Disorder1 trial

A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

Completed· Pfizer logo

Pfizer·Phase 2·NCT00531752·66 enrolled

Narcolepsy1 trial

A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy

Completed· Pfizer logo

Pfizer·Phase 2·NCT01006122·95 enrolled

Mild to Moderate Alzheimer's Disease1 trial

A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease

Terminated· Pfizer logo

Pfizer·Phase 1·NCT01028911·9 enrolled

Schizophrenia1 trial

Add On Treatment for Cognitive Deficits in Schizophrenia

Completed·UUniversity of Pennsylvania·Phase 1·NCT01346163·16 enrolled

1 more indication

Safety and Efficacy1 trial

Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome

Withdrawn· Pfizer logo

Pfizer·Phase 2·NCT01475383

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for PF-03654746. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PF-03654746 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PF-03654746. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Pfizer

PF-03654746

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Allergic Rhinitis1 trial

Attention Deficit Hyperactivity Disorder1 trial

Narcolepsy1 trial

Mild to Moderate Alzheimer's Disease1 trial

Schizophrenia1 trial

Safety and Efficacy1 trial

References

Drug Info

Quick Facts

Related News